Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Tamara Lotan"'
Autor:
Edward M, Schaeffer, Sandy, Srinivas, Nabil, Adra, Yi, An, Daniel, Barocas, Rhonda, Bitting, Alan, Bryce, Brian, Chapin, Heather H, Cheng, Anthony Victor, D'Amico, Neil, Desai, Tanya, Dorff, James A, Eastham, Thomas A, Farrington, Xin, Gao, Shilpa, Gupta, Thomas, Guzzo, Joseph E, Ippolito, Michael R, Kuettel, Joshua M, Lang, Tamara, Lotan, Rana R, McKay, Todd, Morgan, George, Netto, Julio M, Pow-Sang, Robert, Reiter, Mack, Roach, Tyler, Robin, Stan, Rosenfeld, Ahmad, Shabsigh, Daniel, Spratt, Benjamin A, Teply, Jonathan, Tward, Richard, Valicenti, Jessica Karen, Wong, Ryan A, Berardi, Dorothy A, Shead, Deborah A, Freedman-Cass
Publikováno v:
Journal of the National Comprehensive Cancer Network : JNCCN. 20(12)
The NCCN Guidelines for Prostate Cancer address staging and risk assessment after a prostate cancer diagnosis and include management options for localized, regional, recurrent, and metastatic disease. The NCCN Prostate Cancer Panel meets annually to
Autor:
Pedram Argani, Andres Matoso, Aparna Pallavajjalla, Lisa Haley, Ming Tseh-Lin, Jessica Ng, C.W. Chow, Tamara Lotan, Rohit Mehra
Publikováno v:
The American journal of surgical pathology. 46(11)
Over the past decade, several distinct novel renal epithelial neoplasms driven by underlying tuberous sclerosis comples ( TSC)/ mammalian target of rapamycin (MTOR) pathway mutations have been described. We report herein two distinctive TSC2 -mutated
Autor:
Thomas Van den Broeck, Lisa Moris, Thomas Gevaert, Elai Davicioni, Bram Boeckx, Diether Lambrechts, Christine Helsen, Florian Handle, Bart Ghesquière, Stefaan Soenen, Elien Smeets, Roy Eerlings, Sarah El Kharraz, Wout Devlies, R. Jeffrey Karnes, Tamara Lotan, Hendrik Van Poppel, Steven Joniau, Frank Claessens
Publikováno v:
Molecular cancer research : MCR. 20(4)
Molecular drivers of metastasis in patients with high-risk localized prostate cancer are poorly understood. Therefore, we aim to study molecular drivers of metastatic progression in patients with high-risk prostate cancer. A retrospective matched cas